Back HCV Treatment

EASL 2015: Merck Hepatitis C Combination Achieves 90% Cure in Advanced Cirrhosis Patients

A 12-week course of treatment with 2 direct-acting antivirals in development by Merck cured hepatitis C virus infection in 90% of people with very advanced cirrhosis and at imminent risk of liver failure, Ira Jacobson of Weill Cornell Medical College reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna. The Phase 2 study looked at the use of the HCV protease inhibitor grazoprevir and the NS5A inhibitor elbasvir in people with Child-Pugh B cirrhosis.

alt

Read more: